Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
PR85030
NEW BRUNSWICK, New Jersey, Aug. 5, 2020 /PRNewswire=KYODO JBN/ --
-- Company working to ensure broad global access to COVID-19 vaccine
candidate, following approval from regulators
Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen
Pharmaceutical Companies have entered into an agreement with the U.S.
government for the large scale domestic manufacturing and delivery in the U.S.
of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine,
Ad26.COV2.S, for use in the United States following approval or Emergency Use
Authorization by the U.S. Food and Drug Administration (FDA).
The Biomedical Advanced Research and Development Authority (BARDA)
part of the U.S. Department of Health and Human Services' Office of the
Assistant Secretary for Preparedness and Response, in collaboration with the
U.S. Department of Defense, is committing over $1 billion for this agreement.
The vaccine will be provided at a global not-for-profit basis for emergency
pandemic use. The U.S. government may also purchase an additional 200 million
doses of Ad26.COV2.S under a subsequent agreement.
"Johnson & Johnson's global team of experts has worked tirelessly alongside
BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to
stop the spread of COVID-19. We greatly appreciate the U.S. government's
confidence in, and support for, our R&D platform and efforts and the
scalability of our vaccine technology. We are scaling up production in the U.S.
and worldwide to deliver a SARS-CoV-2 vaccine for emergency use," said Paul
Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific
Officer, Johnson & Johnson.
Johnson & Johnson's efforts to develop a SARS-CoV-2 vaccine have been
undertaken pursuant to an ongoing research and development collaboration with
BARDA and under the oversight of the FDA. Based on the positive preclinical data
recently published in the peer reviewed journal Nature [https://c212.net/c/link/?t=0&l=en&o=2877164-1&h=1054653261&u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-020-2607-z&a=Nature ], the Phase 1/2a first-in-human clinical trial of the vaccine candidate,
Ad26.COV2.S, is underway in healthy volunteers in the United States and Belgium.
The Company is evaluating one- and two-dose regimens, in its clinical program
and working diligently to ensure broad, global access to the vaccine following
approval or authorization by regulators. Johnson & Johnson aims to meet its
goal to supply more than one billion doses globally through the course of 2021,
provided the vaccine is safe and effective.
Johnson & Johnson's SARS-CoV-2 vaccine program leverages Janssen's AdVac(R)
The same technology was used to develop Janssen's European
Commission-approved Ebola vaccine and construct its HIV, RSV and Zika vaccine
candidates. More than 90,000 individuals have been vaccinated to date using the
Janssen AdVac(R)-based platform.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant
lives, thriving communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every stage of life.
Today, as the world's largest and most broadly-based healthcare company, we are
committed to using our reach and size for good. We strive to improve access and
affordability, create healthier communities, and put a healthy mind, body and
environment within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health for
humanity. Learn more at www.jnj.com. Follow us at @JNJNews
About the Janssen Pharmaceutical Companies
At Janssen, we're creating a future where disease is a thing of the past. We're
the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make
that future a reality for patients everywhere by fighting sickness with
science, improving access with ingenuity, and healing hopelessness with heart.
We focus on areas of medicine where we can make the biggest difference:
Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines,
Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at
www.janssen.com. Follow us at @JanssenGlobal [https://c212.net/c/link/?t=0&l=en&o=2877164-1&h=1842455742&u=https%3A%2F%2Ftwitter.com%2FJanssenGlobal&a=%40JanssenGlobal ].
Notice to Investors Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995 regarding development of
potential preventive and treatment regimens for COVID-19. The reader is
cautioned not to rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize, actual
results could vary materially from the expectations and projections of Janssen
Pharmaceuticals Inc., and/or Johnson & Johnson. Risks and uncertainties
include, but are not limited to: challenges and uncertainties inherent in
product research and development, including the uncertainty of clinical success
and of obtaining regulatory approvals; uncertainty of commercial success;
manufacturing difficulties and delays; competition, including technological
advances, new products and patents attained by competitors; challenges to
patents; product efficacy or safety concerns resulting in product recalls or
regulatory action; changes in behavior and spending patterns of purchasers of
health care products and services; changes to applicable laws and regulations,
including global health care reforms; and trends toward health care cost
containment. A further list and descriptions of these risks, uncertainties and
other factors can be found in Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended December 29, 2019, including in the sections
captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A.
Risk Factors," and in the company's most recently filed Quarterly Report on
Form 10-Q, and the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the
Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any
forward-looking statement as a result of new information or future events or developments.
Logo - https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg
SOURCE Johnson & Johnson
CONTACT: Jake Sargent, +1 202-569-5086, JSargen3@its.jnj.com, Seema Kumar, +1
908-405-1144SKumar10@its.jnj.com, Katie Buckley, +44 7900-655-261,
KBuckle8@its.jnj.com, Investor Relations: Chris DelOrefice, +1 732-524-2955,
Jennifer McIntyre, +1 732-524-3922
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。